These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 30227753)

  • 21. Emerging drugs for ocular hypertension.
    Lee AJ; Goldberg I
    Expert Opin Emerg Drugs; 2011 Mar; 16(1):137-61. PubMed ID: 21352074
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Studies on the ocular hypotensive effects of prostaglandin F2 alpha ester prodrugs and receptor selective prostaglandin analogs.
    Woodward DF; Chan MF; Burke JA; Cheng-Bennett A; Chen G; Fairbairn CE; Gac T; Garst ME; Gluchowski C; Kaplan LJ
    J Ocul Pharmacol; 1994; 10(1):177-93. PubMed ID: 8207325
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Omidenepag isopropyl for the treatment of glaucoma and ocular hypertension.
    Ferro Desideri L; Cutolo CA; Barra F; Ferrero S; Traverso CE
    Drugs Today (Barc); 2019 Jun; 55(6):377-384. PubMed ID: 31250842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostaglandin analogues in the treatment of glaucoma.
    Lindén C; Alm A
    Drugs Aging; 1999 May; 14(5):387-98. PubMed ID: 10408738
    [TBL] [Abstract][Full Text] [Related]  

  • 25.
    DI Staso S; Agnifili L; Cecannecchia S; DI Gregorio A; Ciancaglini M
    In Vivo; 2018; 32(2):211-220. PubMed ID: 29475902
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells.
    Sharif NA; Kelly CR; Crider JY; Williams GW; Xu SX
    J Ocul Pharmacol Ther; 2003 Dec; 19(6):501-15. PubMed ID: 14733708
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical pharmacology of AL-12182, a new ocular hypotensive 11-oxa prostaglandin analog.
    Sharif NA; McLaughlin MA; Kelly CR; Xu S; Crider JY; Williams GW; Parker JL
    J Ocul Pharmacol Ther; 2006 Oct; 22(5):291-309. PubMed ID: 17076623
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of glaucoma by prostaglandin agonists and beta-blockers in combination directly reduces pro-fibrotic gene expression in trabecular meshwork.
    Tejwani S; Machiraju P; Nair AP; Ghosh A; Das RK; Ghosh A; Sethu S
    J Cell Mol Med; 2020 May; 24(9):5195-5204. PubMed ID: 32267082
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A review of the use of latanoprost for glaucoma since its launch.
    Digiuni M; Fogagnolo P; Rossetti L
    Expert Opin Pharmacother; 2012 Apr; 13(5):723-45. PubMed ID: 22348427
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recovery of deepening of the upper eyelid sulcus after switching from prostaglandin FP receptor agonists to EP2 receptor agonist: a 3-month prospective analysis.
    Sakata R; Fujishiro T; Saito H; Nakamura N; Honjo M; Shirato S; Miyamoto E; Yamada Y; Aihara M
    Jpn J Ophthalmol; 2021 Sep; 65(5):591-597. PubMed ID: 34283308
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of tafluprost 0.0015% and timolol maleate 0.5% fixed combination in patients with ocular hypertension or open-angle glaucoma.
    Lorenz K; Pfeiffer N
    Expert Opin Pharmacother; 2014 Oct; 15(15):2255-62. PubMed ID: 25170534
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Latanoprost : an update of its use in glaucoma and ocular hypertension.
    Perry CM; McGavin JK; Culy CR; Ibbotson T
    Drugs Aging; 2003; 20(8):597-630. PubMed ID: 12795627
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances in the discovery of novel agents for the treatment of glaucoma.
    Mincione F; Nocentini A; Supuran CT
    Expert Opin Drug Discov; 2021 Oct; 16(10):1209-1225. PubMed ID: 33914670
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endothelin antagonism: effects of FP receptor agonists prostaglandin F2alpha and fluprostenol on trabecular meshwork contractility.
    Thieme H; Schimmat C; Münzer G; Boxberger M; Fromm M; Pfeiffer N; Rosenthal R
    Invest Ophthalmol Vis Sci; 2006 Mar; 47(3):938-45. PubMed ID: 16505027
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostaglandin effects on the contractility of bovine trabecular meshwork and ciliary muscle.
    Krauss AH; Wiederholt M; Sturm A; Woodward DF
    Exp Eye Res; 1997 Mar; 64(3):447-53. PubMed ID: 9196397
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of 13-oxa prostaglandin analogs as antiglaucoma agents: synthesis and biological activity.
    Feng Z; Hellberg MR; Sharif NA; McLaughlin MA; Williams GW; Scott D; Wallace T
    Bioorg Med Chem; 2009 Jan; 17(2):576-84. PubMed ID: 19101156
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Mechanisms, clinical profile and role of prostaglandin and prostamide analogues in antiglaucomatous therapy].
    Yu A; Welge-Lüßen U
    Klin Monbl Augenheilkd; 2013 Feb; 230(2):127-32. PubMed ID: 23335086
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Update on the role of alpha-agonists in glaucoma management.
    Arthur S; Cantor LB
    Exp Eye Res; 2011 Sep; 93(3):271-83. PubMed ID: 21524649
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic Drugs and Devices for Tackling Ocular Hypertension and Glaucoma, and Need for Neuroprotection and Cytoprotective Therapies.
    Sharif NA
    Front Pharmacol; 2021; 12():729249. PubMed ID: 34603044
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: design, development, and place in therapy.
    Addis VM; Miller-Ellis E
    Clin Ophthalmol; 2018; 12():2649-2657. PubMed ID: 30587912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.